Alpha 2.0
Login Register
» Authors » Hien Liu

Hien Liu

Explore the profile of Hien Liu including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 35
Citations 228
Followers 0
Related Specialties
Hematology
Oncology
General Surgery
Top 10 Co-Authors
Taiga Nishihori
Farhad Khimani
Aleksandr Lazaryan
Robert Dean
Matt Kalaycio
Rawan Faramand
Ronald Sobecks
Brad Pohlman
Hany Elmariah
Navneet S Majhail
Published In
Transplant Cell Ther
Biol Blood Marrow Transplant
Blood Adv
Hematol Oncol Stem Cell Ther
J Clin Apher
Affiliations
Soon will be listed here.
Recent Articles
1.
Comparison of Outcomes of Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Older Versus Younger Patients
Adoncecchi G, Kumar A, Mogili K, Faramand R, Liu H, Khimani F, et al.
Cancers (Basel) . 2025 Jan; 17(2). PMID: 39858092
Background: Previous studies have shown that allogeneic peripheral blood stem cell transplantation (PBSCT) from an HLA haploidentical (haplo) donor followed by graft-versus-host disease (GVHD) prophylaxis with post-transplant cyclophosphamide (PTCy) results...
2.
Lower Weight-Based Mycophenolate Mofetil Dosing is Associated with Superior Outcomes after Haploidentical Hematopoietic Cell Transplant with Post-transplant Cyclophosphamide
Elmariah H, Otoukesh S, Kumar A, Ali H, Arslan S, Dimaggio E, et al.
Transplant Cell Ther . 2024 Aug; 30(10):1019.e1-1019.e9. PMID: 39102983
Mycophenolate mofetil (MMF) is commonly included in post-transplant cyclophosphamide (PTCy) based graft-versus-host disease (GVHD) prophylaxis after haploidentical (haplo) hematopoietic cell transplant (HCT). In the non-PTCy setting, higher MMF dose/kg has...
3.
Mismatched donor allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide achieves comparable outcomes between racially and ethnically diverse patient populations
Caprice T, Fan W, Kim J, Faramand R, Mishra A, Perez L, et al.
Am J Hematol . 2024 Mar; 99(6):1196-1200. PMID: 38546371
No abstract available.
4.
Simple Score of Albumin and CRP Predicts High-Grade Toxicity in Patients with Multiple Myeloma Receiving CAR-T Therapy
Akhtar O, Modi K, Kim J, Skelson L, Smith E, Al-Jumayli M, et al.
Transplant Cell Ther . 2023 Dec; 30(3):283.e1-283.e10. PMID: 38123069
Administration of chimeric-antigen receptor T-cell (CAR-T) therapy is complex and associated with unique toxicities. Identifying patients at risk for inferior outcomes is important for individualized management. The Glasgow-prognostic score (GPS)...
5.
Sirolimus Is an Acceptable Alternative to Tacrolimus for Graft-versus-Host Disease Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide
Elmariah H, Otoukesh S, Kumar A, Ali H, Arslan S, Shouse G, et al.
Transplant Cell Ther . 2023 Nov; 30(2):229.e1-229.e11. PMID: 37952648
Graft-versus-host disease (GVHD) prophylaxis with post-transplantation cyclophosphamide (PTCy), tacrolimus (Tac), and mycophenolate mofetil (MMF) for allogeneic haploidentical donor (haplo) hematopoietic cell transplantation (HCT) results in comparable outcomes to matched unrelated...
6.
Patient-Reported Outcomes among Multiple Myeloma Patients Treated with Standard of Care Idecabtagene Vicleucel
Oswald L, Gudenkauf L, Li X, De Avila G, Peres L, Kirtane K, et al.
Cancers (Basel) . 2023 Oct; 15(19). PMID: 37835405
Idecabtagene vicleucel (ide-cel) was the first FDA-approved chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma (RRMM) patients. This was the first study to evaluate patient-reported outcomes (PROs) among RRMM...
7.
Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: A systematic review and meta-analysis
Akhtar O, Sheeba B, Azad F, Alessi L, Hansen D, Alsina M, et al.
J Geriatr Oncol . 2023 Sep; 15(2):101628. PMID: 37723045
Introduction: Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR-T) therapy is transforming the care of patients with relapsed/refractory multiple myeloma (MM). Unfortunately, despite being a disease of older adults...
8.
The Cell and Gene Therapy Consortium's Perspective on Harmonizing Data Collection for Patient Enrollment, Therapy Ordering and Scheduling, and Cell Collection
Mora A, Barnes L, Divine C, Frey N, Fuchs C, Hayes B, et al.
Transplant Cell Ther . 2023 Aug; 29(11):653-665. PMID: 37604251
Established in October 2021, the Cell and Gene Therapy (CGT) Consortium convened with the goal to bring together key CGT stakeholders - manufacturers, treatment centers, regulators, services providers, and ecosystem...
9.
Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma
Lee D, Kumar A, Mohammed T, Peres L, Alsina M, Bachmeier C, et al.
Blood Adv . 2023 Jun; 7(16):4247-4257. PMID: 37307173
Idecabtagene vicleucel (ide-cel) is a type of B-cell maturation antigen (BCMA)-targeting chimeric antigen receptor T-cell (CAR-T) approved for the treatment of relapsed and refractory multiple myeloma (RRMM). Currently, the incidence...
10.
The Impact of Pre-Apheresis Health Related Quality of Life on Peripheral Blood Progenitor Cell Yield and Donor's Health and Outcome: Secondary Analysis of Patient-Reported Outcome Data from the RDSafe and BMT CTN 0201 Clinical Trials
Farhadfar N, Ahn K, Bo-Subait S, Logan B, Stefanski H, Hsu J, et al.
Transplant Cell Ther . 2022 Jun; 28(9):603.e1-603.e7. PMID: 35688325
There is a lack of evidence about how health-related quality of life (HRQoL), including psychosocial factors, might affect donation-related experiences and clinical markers in the context of hematopoietic stem cell...